Aditya Bardia

1 month ago | mdpi.com | Hope Rugo |Aditya Bardia |Peter Schmid |Sara M. Tolaney

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

2 months ago | ajmc.com | Pearl Steinzor |Aditya Bardia

In part 2 of this interview, we continue our discussion with Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, on recent findings from the TROPION-Breast01 trial (NCT05104866), presented at an ESMO Virtual Plenary in February 2025. In this discussion, Bardia covers the need for subgroup analyses, managing adverse events, and ongoing studies involving TROP2-directed antibody drug conjugates (ADCs). This transcript was lightly edited and captions were auto generated.

2 months ago | ajmc.com | Pearl Steinzor |Aditya Bardia

In January, the FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for adult patients with unresectable or metastatic/HR-positive, HER2-negative breast cancer who have previously received endocrine-based therapy and chemotherapy.1The approval is based on findings in TROPION-Breast01 (NCT05104866), presented at an ESMO Virtual Plenary in February 2025. Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses these findings.

2 months ago | targetedonc.com | Jordyn Sava |Aditya Bardia

0:45 | About the approval 1:16 | Dato-DXd's mechanism of action 2:00 | Behind TROPION-Breast01 3:03 | Key findings from the study 3:52 | Overall survival findings 4:57 | Future biomarkers 5:35 | Real world recommendations 7:14 | Future development of ADCs In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan (Dato-DXd) for the treatment of patients with unresectable or metastatic hormone receptor-positive (HR+),...

Dec 10, 2024 | onclive.com | Aditya Bardia

CommentaryVideoDecember 10, 2024Author(s):Fact checked by:,Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.